Literature DB >> 30932757

Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study.

Emily A Whelan1, Ross J Mason1, Jeffrey G Himmelman1, Kara Matheson2, Ricardo A Rendon1.   

Abstract

PURPOSE: We report the natural history of small renal masses in patients undergoing active surveillance with extended followup.
MATERIALS AND METHODS: We performed a prospective cohort study in patients undergoing active surveillance of small renal masses diagnosed between 2001 and 2011 at a single institution. All patients underwent active surveillance of small renal masses presumed to be renal cell carcinoma based on diagnostic imaging. Reported patient outcomes included progression to treatment, metastatic disease and/or death. Linear and volumetric tumor growth rates were evaluated.
RESULTS: Included in study were 103 patients with a total of 107 small renal masses. Median followup was 55.5 months in patients who continued on active surveillance. Median maximum diameter and volume at diagnosis were 2.1 cm (IQR 1.5-2.7) and 4.8 cm3 (IQR 1.7-11.9), respectively. At last followup 53 patients (51.5%) were alive without metastatic disease, 48 (45.6%) had died of another cause and metastatic disease had developed in 2 (1.9%), including 1 (1.0%) who ultimately died of metastatic renal cell carcinoma. The mean ± SEM linear and volumetric growth rates of all small renal masses were 0.21 ± 0.03 cm per year and 6.15 ± 2.15 cm3, respectively. Study limitations include nonstandardized followup and a lack of biopsy data on most patients.
CONCLUSIONS: During extended followup the majority of small renal masses in patients on active surveillance display indolent behavior. The risk of progression to metastatic disease remains low.

Entities:  

Keywords:  carcinoma; kidney neoplasms; morbidity; neoplasm metastasis; renal cell; watchful waiting

Mesh:

Year:  2019        PMID: 30932757     DOI: 10.1097/JU.0000000000000075

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Safety and delayed intervention rates of active surveillance for small renal masses in an elderly population.

Authors:  Brian T Kadow; Marc C Smaldone
Journal:  Ann Transl Med       Date:  2019-09

2.  Visualisation of focal renal lesions on ultrasound: A review of 518 lesions with contrast CT correlation.

Authors:  Blanche Wylie; Martin Necas; Aine Heaney
Journal:  Australas J Ultrasound Med       Date:  2020-11-02

3.  Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.

Authors:  Arun R Menon; Ahmed A Hussein; Kristopher M Attwood; Tashionna White; Gaybrielle James; Bo Xu; Michael Petroziello; Charles L Roche; Eric C Kauffman
Journal:  J Urol       Date:  2021-03-29       Impact factor: 7.600

4.  Small Renal Masses without Gross Fat: What Is the Role of Contrast-Enhanced MDCT?

Authors:  Gerta Repeckaite; Kristina Zviniene; Justina Jankauskiene; Algidas Basevicius; Daimantas Milonas
Journal:  Diagnostics (Basel)       Date:  2022-02-21

5.  Differential diagnosis and prognosis of small renal masses: association with collateral vessels detected using contrast-enhanced computed tomography.

Authors:  Masato Yanagi; Tomonari Kiriyama; Jun Akatsuka; Yuki Endo; Hayato Takeda; Akifumi Katsu; Yuichiro Honda; Kyota Suzuki; Yoshihiro Nishikawa; Shunsuke Ikuma; Hikaru Mikami; Yuka Toyama; Go Kimura; Yukihiro Kondo
Journal:  BMC Cancer       Date:  2022-08-05       Impact factor: 4.638

6.  Diagnostic accuracy of contrast-enhanced ultrasound in the detection of small renal masses: A protocol of systematic review and meta-analysis.

Authors:  Jiang-Feng Wu; Chao Wu; Yun-Lai Wang; Zheng-Ping Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

7.  Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative.

Authors:  Amit K Patel; Craig G Rogers; Anna Johnson; Sabrina L Noyes; Ji Qi; David Miller; Edward Shervish; Benjamin Stockton; Brian R Lane
Journal:  Eur Urol Open Sci       Date:  2020-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.